CORRECTION
Published on 10 Nov 2021
Corrigendum: Safety of Semaglutide
doi 10.3389/fendo.2021.786732
- 6,531 views
- 4 citations
- Frontiers in Endocrinology
- Clinical Diabetes
- Research Topics
- Reviews and Novel Clinical Perspectives on Semaglutide: A GLP-1 Receptor Agonist with Both Injectable and Oral Formulations
Reviews and Novel Clinical Perspectives on Semaglutide: A GLP-1 Receptor Agonist with Both Injectable and Oral Formulations
62k
Total downloads
335k
Total views and downloads
Submit your idea
You will be redirected to our submission process.
Articles
EDITORIAL
Published on 23 Sep 2021
Editorial: Reviews and Novel Clinical Perspectives on Semaglutide: A GLP-1 Receptor Agonist With Both Injectable and Oral Formulations
doi 10.3389/fendo.2021.760153
- 2,680 views
- 2 citations
REVIEW
Published on 07 Jul 2021
Safety of Semaglutide
doi 10.3389/fendo.2021.645563
- 303,957 views
- 150 citations
REVIEW
Published on 29 Jun 2021
Clinical Perspectives on the Use of Subcutaneous and Oral Formulations of Semaglutide
doi 10.3389/fendo.2021.645507
- 16,093 views
- 47 citations
REVIEW
Published on 25 Jun 2021
Efficacy of Semaglutide in a Subcutaneous and an Oral Formulation
doi 10.3389/fendo.2021.645617
- 96,470 views
- 67 citations
REVIEW
Published on 29 Mar 2021
Cardiovascular Safety and Benefits of Semaglutide in Patients With Type 2 Diabetes: Findings From SUSTAIN 6 and PIONEER 6
doi 10.3389/fendo.2021.645566
- 25,236 views
- 65 citations
Published in
Frontiers in Endocrinology
- Clinical Diabetes
Impact
- 335kTopic views
- 271kArticle views
- 62kArticle downloads